Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disease flare after EGFR tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancer.

Pathology oncology research : POR - 1 Oct 2013

Chen Hua-Jun, Yan Hong-Hong, Yang Jin-Ji, Chen Zhi-Hong, Su Jian, Zhang Xu-Chao, Wu Yi-Long

Abstract excerpt

Available study revealed non-small cell lung cancer (NSCLC) patients faced a risk of disease flare after cessation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. There was no data concerning the prognostic value of disease flare. This study aimed to investigate the prevalence of disease flare in a Chinese cohort, and analyzed its prediction to survival. A cohort of 227 NSCLC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Disease Progression

Share to ErbB Receptors

Share to Prevalence

Share to Protein Kinase Inhibitors

Share to Substance Withdrawal Syndrome

Source

Identifiers

PMID: 23716023
DOI: 10.1007/s12253-013-9651-z

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disease flare after EGFR tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancer.PMID 23716023Read ↗

Disease flare after gefitinib discontinuation.Semantic proximity Read ↗

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.Semantic proximity Read ↗

Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors Following Disease Progression or RelapseSemantic proximity Read ↗

[Retreatment with epidermal growth factor receptor inhibitor after initial failure in advanced non-small cell lung cancer].Semantic proximity Read ↗

Maintenance therapy for metastatic non-squamous non-small cell lung cancer: lymphopenia as a biomarker for pemetrexed cessationSemantic proximity Read ↗

Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation.Semantic proximity Read ↗

Osimertinib and chemotherapy combination to treat brain metastasis flare and osimertinib resistance by EGFR C797S.Semantic proximity Read ↗

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.Semantic proximity Read ↗

Readministration of EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients after initial failure, what affects its efficacy?Semantic proximity Read ↗

Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib.Semantic proximity Read ↗

Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.Semantic proximity Read ↗

Chemotherapy should be performed in epidermal growth factor receptor mutation-positive lung adenocarcinoma patients who had progressive disease to the first epidermal growth factor receptor-tyrosine kinase inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.